A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Weekly Intravenous Administration of 7.5mg and 0.075mg/kg Alefacept in Subjects Weighing Between 100kg and 150kg, With Moderate to Severe Chronic Plaque Psoriasis

Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis

Inclusion Criteria:

• Body weight between 100kg and 150kg
• Diagnosis of Chronic Plaque Psoriasis with Body Surface Area (BSA) involvement of ≥ 10%
• Candidate for phototherapy or systemic therapy for Psoriasis
• CD4 + T lymphocyte counts > lower limit of normal

Exclusion Criteria:

• Clinically significant abnormal hematology values or blood chemistry values
• ALT or AST value of ≥ 3x the upper limit of normal
• Other types of Psoriasis
• Serious infection within 3 months prior to 1st dose of study drug
• Antibody positive for HIV
• History of malignancy
• History of severe allergic or anaphylactic reactions
• History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease